Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.

BMC cancer·2015
Same author

Leukemia. Q&A highlights.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2007
Same author

Chronic myeloid leukemia in 2007.

Journal of managed care pharmacy : JMCP·2007
Same author

Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2007
Same author

Monitoring your patients with chronic myeloid leukemia.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2006

Related Experiment Video

Updated: Jul 9, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Chronic myeloid leukemia in 2007.

Jolynn Sessions1

  • 1Hematology/Oncology, Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA. jolynn_sessions@emoryhealthcare.org

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|December 11, 2007
PubMed
Summary

Chronic myeloid leukemia (CML) is a cancer affecting blood cell development. Advances in BCR-ABL tyrosine kinase inhibitors have improved patient outcomes, making monitoring crucial for managing CML effectively.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Related Experiment Videos

Last Updated: Jul 9, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm accounting for 15-20% of adult leukemias.
  • CML is characterized by the Philadelphia Chromosome (Ph) or BCR-ABL fusion gene, leading to uncontrolled cell growth.
  • The disease progresses through chronic, accelerated, and blast crisis phases, with advanced stages associated with poor prognosis.

Purpose of the Study:

  • To review the epidemiology, staging, biology, and monitoring techniques for Chronic Myeloid Leukemia (CML).
  • To highlight the impact of novel therapies on CML patient outcomes.
  • To emphasize the importance of continuous patient monitoring for effective disease management.

Main Methods:

  • Review of existing literature on CML.
  • Discussion of diagnostic methods including cytogenetics and PCR.
  • Analysis of therapeutic strategies targeting BCR-ABL.

Main Results:

  • The identification of the BCR-ABL oncogene has led to the development of targeted tyrosine kinase inhibitor therapies.
  • These therapies have significantly improved survival rates, allowing many patients to remain in the chronic phase indefinitely.
  • Effective monitoring using blood counts, cytogenetics, and quantitative PCR is essential for assessing treatment response and detecting disease progression.

Conclusions:

  • Understanding BCR-ABL biology has revolutionized CML treatment, offering long-term disease control.
  • Continuous monitoring is vital for managing CML patients, especially with advanced therapies.
  • Comprehensive assessment of disease status through various tests ensures optimal patient management and improved prognosis.